Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 4/20 | 0.32 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.32 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.32 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13822005 | 1.00 | FUCA1 (0.52) | FUCA1L3MBTL1ALDH1A1TSHRLMNA | |
| SCHEMBL154476 | 1.00 | FUCA1 (0.52) | FUCA1L3MBTL1ALDH1A1TSHRLMNA | |
| SCHEMBL6534721 | 1.00 | FUCA1 (0.52) | FUCA1L3MBTL1ALDH1A1TSHRLMNA | |
| SCHEMBL10045765 | 1.00 | FUCA1 (0.52) | FUCA1L3MBTL1ALDH1A1TSHRLMNA | |
| SCHEMBL12205165 | 1.00 | FUCA1 (0.52) | FUCA1L3MBTL1ALDH1A1TSHRLMNA | |
| SCHEMBL12921945 | 1.00 | FUCA1 (0.52) | FUCA1L3MBTL1ALDH1A1TSHRLMNA | |
| SCHEMBL423526 | 1.00 | FUCA1 (0.52) | FUCA1L3MBTL1ALDH1A1TSHRLMNA | |
| SCHEMBL20844917 | 1.00 | FUCA1 (0.52) | FUCA1L3MBTL1ALDH1A1TSHRLMNA | |
| SCHEMBL22472219 | 1.00 | FUCA1 (0.52) | FUCA1L3MBTL1ALDH1A1TSHRLMNA | |
| SCHEMBL31384230 | 1.00 | FUCA1 (0.52) | FUCA1L3MBTL1ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| WO-2024098039-A2 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230346905-A1 | PENTAVALENT VACCINE AGAINST NEISSERIA MENINGITIDIS COMPRISING A SYNTHETIC MEN A ANTIGEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-02 | — | — | US | disclosed |
| US-20230346905-A1 | PENTAVALENT VACCINE AGAINST NEISSERIA MENINGITIDIS COMPRISING A SYNTHETIC MEN A ANTIGEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-02 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| EP-4200022-A1 | TRIPTOLIDE CONJUGATES AND USES THEREOF | Reyoung Corporation (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2009018431-A2 | NOVEL SYNTHETIC AGONISTS OF TLR9 | IDERA PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | IDERA PHARMACEUTICALS, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080089883-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | IDERA PHARMACEUTICALS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7338940-B2 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J | 2008-03-04 | — | — | US | disclosed |
| US-7338940-B2 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J | 2008-03-04 | — | — | US | disclosed |
| US-7335500-B2 | Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335500-B2 | Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-02-26 | — | — | US | disclosed |
| WO-2008007153-A2 | ANTIVIRAL COMPOUNDS | IQUR LTD. (GB) | 2008-01-17 | — | — | WO | disclosed |
| US-7160865-B2 | Heterocyclic alcohols such as 2-deoxy-D-glucose or 5-thio-D-glucose, used as anticarcinogenic agents or angiogenesis inhibitors; glycolysis antagonists | LAMPIDIS THEODORE J | 2007-01-09 | — | — | US | disclosed |
| US-7160865-B2 | Heterocyclic alcohols such as 2-deoxy-D-glucose or 5-thio-D-glucose, used as anticarcinogenic agents or angiogenesis inhibitors; glycolysis antagonists | LAMPIDIS THEODORE J | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | FUCA1 24/4885L3MBTL1 2804/4885ALDH1A1 3319/4885 |
| US-20080089883-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | TLR3, TLR9, TLR5 | FUCA1 1492/4885L3MBTL1 1268/4885ALDH1A1 4183/4885 |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | FUCA1 139/4885L3MBTL1 1884/4885ALDH1A1 2349/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | FUCA1 457/4885L3MBTL1 490/4885ALDH1A1 1901/4885 |
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | TLR8, TLR7, TLR9 | FUCA1 2338/4885L3MBTL1 1561/4885ALDH1A1 1872/4885 |
| US-20230346905-A1 | PENTAVALENT VACCINE AGAINST NEISSERIA MENINGITIDIS COMPRISING A SYNTHETIC MEN A ANTIGEN | MEN1, KLK3, NASP | FUCA1 2788/4885L3MBTL1 1170/4885ALDH1A1 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.